Having trouble viewing the email? View it here.

Week in Review
Sign up for this newsletter »Read more at Oncologystat.com »September 25, 2009 | Issue 85

Top Story
Hormone Therapy for Prostate Cancer Raises Heart Disease Risk
Elsevier Global Medical News, 2009 Sept 23, P Wendling
Observational study shows men treated with endocrine therapy are at increased risk of developing and dying from several types of CV disease.
Weekly NewsMore »
Pfizer Reports Sutent Safe and Effective in Asians, Forges Alliances With Major Asian Oncology Centers
The Pink Sheet Daily, 2009 Sept 23, T Sami
Phase IIIb Asian trial demonstrated similar effectiveness and tolerability of multikinase inhibitor in Asians as in non-Asians.
Blues Technology Evaluation Center Joins Chorus: CT Colonography Works, But Costs Too Much
The Gray Sheet, 2009 Sept 21, M Houghton
BlueCross BlueShield TEC agrees with a Medicare committee and AHRQ that CT colonography is an effective screen for colon cancer but is not cost-effective compared to colonoscopy.
Long-Term Data Lacking on Proton Therapy vs Traditional Radiation for Cancer—AHRQ
The Gray Sheet, 2009 Sept 21, M Hogan
Proton therapy is a "promising" cancer treatment, but its potential advantages over alternative radiation therapies remain unproven.
Surgery Improves Survival in Metastatic Breast Cancer
Elsevier Global Medical News, 2009 Sept 21, P Wendling
Women live considerably longer if they undergo surgical removal of the primary tumor rather than palliative treatment, a more common option.
New Reconstruction Surgery Helps Tonsil Cancer Patients Speak and Eat Normally
Elsevier Global Medical News, 2009 Sept 21, MA Moon
A new reconstruction technique allows patients who have undergone surgery to retain the ability to speak clearly and swallow most foods.
PRIMA Trial of Rituximab Maintenance for Follicular Lymphoma Stopped Early Due to PFS Benefit
OncologySTAT Editorial Team, 2009 Sept 18, B Bekiesz
PFS was extended in patients who continued to take rituximab maintenance therapy after initial response to rituximab/chemotherapy.
Pemetrexed Maintenance Improves Lung Cancer Survival
Elsevier Global Medical News, 2009 Sept 18, JS MacNeil
Pemetrexed maintenance therapy improved median overall survival by 2.8 months and median progression-free survival by 1.7 months.
Lung Cancer More Deadly in Women Given Hormone Therapy
Elsevier Global Medical News, 2009 Sept 18, JS MacNeil
Hormone therapy in postmenopausal women increases risk of death from lung cancer, according to a Women's Health Initiative trial analysis.

NEW CME
Earn valuable credits by participating in these case-based online programs in renal cell carcinoma and leukemia.

VISIT SITE

Advertisement.
ECCO/ESMO 2009

Conference news plus interviews with ECCO/ESMO officers.


Elsevier Inc. Home | Site Map | Cancer Types | About OncologySTAT | Privacy Policy | Terms of Use | Contact Us | Advertise

You are currently subscribed as %%email%% | Unsubscribe | Update Your Profile
Was this email forwarded to you? Sign-up for your own free subscription.
Copyright © 2012, Elsevier Inc. All rights reserved.
Elsevier Inc., 1600 John F. Kennedy Boulevard, Suite 1800.
Philadelphia, PA 19103-2899, USA